The glucagon receptor component increases energy expenditure through thermogenesis, promotes hepatic fat oxidation (your liver burns more fat), and stimulates lipolysis (fat cells release their stored triglycerides for use as fuel)
The findings were compelling, tirzepatide not only achieved greater reductions in HbA1c but also delivered significant body weight loss, all while showing a lower incidence of hypoglycemia at the 52-week mark
A phase 2 clinical trial published in JAMA (2023) reported significant reductions in body weight and improvements in metabolic markers
This next-generation design aims to amplify weight loss effects beyond what todays treatments achieve
[3] Trong rut v no, proglucagon c xc tc bi PC 1/3 to ra glicentin, c th c x l thm thnh GRPP v oxyntomodulin, GLP-1, can thip peptide-2 (IP-2) v peptide ging nh glucagon- 2 (IP-2) GLP-2)
Retatrutide is an investigational triple receptor agonist peptide that simultaneously targets and activates the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR)
